Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global extracorporeal carbon dioxide removal (ECCO2R) devices market is likely to be driven by the need to treat conditions of respiratory failure. In recent years, new-generation extracorporeal carbon dioxide removal (ECCO2R) devices have been developed. More efficient venovenous (VV-ECCO2R) devices have become available and replaced the arteriovenous approach, with the advantage of not needing arterial puncture. These devices offer lower resistance to blood flow, have small priming volumes, and offer a significantly more efficient gas exchange with comparatively low extracorporeal blood flows (0.4–1 L/min). With extracorporeal carbon dioxide removal (ECCO2R) the patient’s PaCO2 is chiefly determined by the rate of fresh gas flow through the membrane lung. Significant technical advancements have improved extracorporeal techniques for carbon dioxide removal; such changes may help avoid worsening respiratory failure and respiratory acidosis, and possibly prevent or reduce the duration of IMV in patients with aggravation of COPD and asthma. North America, Europe and Asia are expected to be key markets.
Companies are engaged in providing modern solutions. For example, in 2021, Baxter International Inc. announced the global launch of PrisMax 2, the latest version of the company’s next-generation platform. PrisMax 2 was devised to help simplify administration of continuous renal replacement therapy (CRRT) and other organ support therapies, while offering hospitals the flexibility to fulfil the unique demands of the intensive care unit (ICU). The PrisMax 2 system featured new solutions within the company’s TrueVue digital health portfolio, as well as the PrismaLung+ blood-gas exchanger that delivered extracorporeal carbon dioxide removal (ECCO2R) therapy to support the management of acute respiratory dysfunction. PrisMax 2 and TrueVue were soon to be available in over 20 countries across the United States and Europe. Such developments are expected to drive the global extracorporeal carbon dioxide removal (ECCO2R) devices market.
In 2020, it was reported that US FDA had granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius Medical Care company, for long-term use of its Novalung system for individuals with acute lung failure or acute cardiopulmonary failure. With class II approval, the Novalung system was the first complete system approved for ECMO therapy (ECMO = extracorporeal membrane oxygenation) and long-term use for a duration of over six hours. Additionally, the Novalung system could be used to apply extracorporeal CO2 removal (ECCO2R) for severe lung diseases. The whole system comprised the Novalung console and the XLung kit.
PROLUNG® is a minimally invasive extracorporeal carbon dioxide removal (ECCO2R) system. The low flow extracorporeal CO2 elimination system uses a conventional 13 Fr catheter, which enables improvement of hypercapnia in patients with ARDS, exacerbation of COPD, minimization of risk in lung transplantation, help in reduction of CO2 in cranio-encephalic trauma and acceleration of healing in tissue injuries, thanks to the possibility of reducing volume and pressure in ventilation.
Key Findings of the Report:
Market Analysis by Product, Access, End Use, Application, and Region:
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.